New Delhi, April 8 Biocon Ltd announced on Wednesday that its subsidiary, Biocon Pharma Ltd, has received approval from the US health regulator for its genetically engineered version of dapagliflozin tablets, indicated for reducing blood sugar levels in adults with type 2 diabetes mellitus.The...
biocon ltd
biosimilar insulin
blood sugar control
cardiovascular disease
dapagliflozin
diabetes mellitus
drug approval
generic medicine
glp-1 peptides
heart failure
oralsoliddosageformulations
pharmaceutical manufacturing
tablet
type 2 diabetes
us food and drug administration (usfda)
New Delhi, April 2 Shares of Sai Parenteral, a diversified pharmaceutical formulation company, closed on Thursday with a premium of nearly 4 per cent against the issue price of Rs 392.The stock made its market debut at Rs 405, up 3.32 per cent from the issue price on the BSE. During the day...
bse
contract development and manufacturing organization
equity shares
financial markets
global formulations
india
initial public offering (ipo)
injectable products
investment
market valuation
nse
oralsoliddosageformulations
pharmaceutical formulation company
sai parenteral
stock market
New Delhi, March 27 The initial public offering (IPO) of Sai Parenteral, a diversified pharmaceutical formulation company, was fully subscribed on the final day of bidding on Friday, thanks to investments from institutional investors.The IPO received bids for 78,80,972 shares, compared to the...
New Delhi, March 25 The initial public offering of Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, saw 41 per cent subscription on the second day of the share sale on Wednesday.The IPO received bids for 30,82,788 shares against 75,22,486 shares on offer, according to...
anchor investors
contract development and manufacturing organization
equity shares
global formulations
initial public offering
injectable products
ipo subscription
new delhi
oralsoliddosageformulations
pharmaceutical formulation
price band
qualified institutional buyers
retail individual investors
sai parenteral's ltd
share sale
New Delhi, March 24 The initial public offering of Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, received 4% subscription on the first day of bidding on Tuesday.According to NSE data, the IPO received bids for 3,35,350 shares against 75,22,486 shares on offer.The...
capital markets
contract development and manufacturing organization
equity shares
global formulations
india
initial public offering
injectable products
investment
ipo subscription
new delhi
oralsoliddosageformulations
pharmaceutical formulation
price band
public offering
sai parenteral
New Delhi, March 23 Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, raised over Rs 122 crore from anchor investors on Monday, a day before its initial public offering (IPO) opens for subscription.Morgan Stanley Asia (Singapore) Pte Ltd, Kotak Lifesciences Fund, Quant...
anchor investors
capital raising
contract development
equity shares
global formulations
hyderabad
india
initial public offering
injectable products
ipo
manufacturing organization
new delhi
oralsoliddosageformulations
pharmaceutical formulation
sai parenteral
Hyderabad, March 17 Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, announced on Tuesday that it has fixed the price band for its proposed IPO at ₹372-₹392 per share.The company has filed its Red Herring Prospectus (RHP) with the Securities and Exchange Board of India...
business expansion
contract development and manufacturing organisation
corporate finance
equity shares
financial
global formulations
initial public offering
injectable products
investment
ipo
oralsoliddosageformulations
pharmaceutical formulation
red herring prospectus
sai parenteral's ltd
securities and exchange board of india
stock exchange